Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PROPRANOLOL

All products: not a benefit

Other products in the same Health Canada class (C07A, C07AA) — coverage varies; not interchangeable

  • Nadolol (Corgard): general benefit, Not a benefit
  • Sotalol (Sotacor): general benefit, Not a benefit
  • Timolol (Blocadren): general benefit, Not a benefit
  • Acebutolol (Sectral): general benefit, Not a benefit
  • Atenolol (Apo-Atenol): general benefit
  • Bisoprolol (Sandoz Bisoprolol Tablets): general benefit, Not a benefit

3 more in the class list below

Inderal-LA · DIN 02042266 · 120mg · LA capsule

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.Discontinued 2022-05-31 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Hemangiol; DOSAGE FORM/ STRENGTH: 3.75mg/mL oral solution — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Propranolol Brand(s): Hemangiol DOSAGE FORM/ STRENGTH: 3.75mg/mL oral solution Effective date: October 29, 2018 Initial Criteria: For the treatment of infants and children with any of the following proliferating infantile hemangiomas; • Life or function-threatening hemangioma OR • Ulcerated hemangioma in those experiencing pain and/or lack of response to simple wound care measures; OR • Hemangiomas deemed to put the patient at risk of permanent scarring or disfigurement. Requests must be from a dermatologist or a physician experienced in the care of infantile hemangiomas. Duration of approval: up to 12 months1 1 Note that the treatment duration is typically 6 months and consideration should be made to discontinue the product in the absence of improvement within the first 2 months. Renewals: Renewals will be considered on a case-by-case basis. If wounds are not healing, please provide clinical information as to why ongoing reimbursement is required. 114 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 114, record 71, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Inderal-LA · DIN 02042266 Manufacturer: Pfizer Canada Inc.; listing date 2023-04-28 Health Canada: Cancelled post market since 2022-05-31 · brand INDERAL-LA · ATC C07AA05 PROPRANOLOL · form Capsule (extended-release) · route Oral · ingredients PROPRANOLOL HYDROCHLORIDE 120 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Inderal-LA: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16124 · Verify on the e-Formulary ↗ (DIN 02042266)

Source record
DIN 02042266: Inderal-LA Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400060; group id 290; item number 0624; lccId None; manufacturer id PFI Source form: LA Cap; strength: 120mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02042266 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16124
Interchangeable products
Lupin-Propranolol LA · DIN 02491915 · not recorded
Shortage status: active shortage (reported 2022-02-24, last updated 2022-02-25) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02042266
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

NADOLOL

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 40mg, 80mg, 160mg · Tab

SOTALOL HCL

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 80mg, 160mg · Tab

TIMOLOL MALEATE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

CARVEDILOL

· 36 products · Listed, not a benefit (4), Limited Use, codes 183 (32) · strengths: 3.125mg, 6.25mg, 12.5mg, 25mg · Tab

NEBIVOLOL HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS A) HYPERTENSION TEVA-PROPRANOLOL (propranolol hydrochloride) is indicated in the treatment of mild to moderate hypertension. It is usually used in combination with other drugs, particularly a thiazide diuretic. TEVA-PROPRANOLOL may, however, in certain patients be used alone or as an initial agent in those patients in whom, in the judgment of the physician, treatment should be started with a beta-blocker rather than a diuretic. The combination of TEVA-PROPRANOLOL with thiazide-like diuretics and/or peripheral vasodilators has been shown to be compatible and generally more effective than TEVA-PROPRANOLOL alone. Experience with most commonly used antihypertensive agents has not suggested evidence of incompatibility. TEVA-PROPRANOLOL is not recommended for the emergency treatment of hypertensive crises. B) ANGINA PECTORIS TEVA-PROPRANOLOL is indicated for the prophylaxis of angina pectoris. C) CARDIAC ARRHYTHMIAS 1) Supraventricular arrhythmias a) Paroxysmal atrial tachycardias, particularly those arrhythmias induced by catecholamines o… https://pdf.hres.ca/dpd_pm/00014382.PDF PM date: not printed or not captured Source product: TEVA-PROPRANOLOL; DIN 00496480; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Inderal-LA · DIN 02042266 Shortage status: active shortage (reported 2022-02-24, last updated 2022-02-25) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02042266

Check this DIN again

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated September 15, 2026

Propranolol (Hemangiol)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: For the treatment of infants and children with any of the following proliferating infantile hemangiomas;

Ministry criteria corpus 2025-01-01; page 114

Propranolol Brand(s): Hemangiol DOSAGE FORM/ STRENGTH: 3.75mg/mL oral solution Effective date: October 29, 2018
Initial Criteria:
For the treatment of infants and children with any of the following proliferating infantile hemangiomas;
• Life or function-threatening hemangioma OR
• Ulcerated hemangioma in those experiencing pain and/or lack of response to simple wound care measures; OR
• Hemangiomas deemed to put the patient at risk of permanent scarring or disfigurement.
Requests must be from a dermatologist or a physician experienced in the care of infantile hemangiomas.
Duration of approval: up to 12 months1 1 Note that the treatment duration is typically 6 months and consideration should be made
to discontinue the product in the absence of improvement within the first 2 months.
Renewals: Renewals will be considered on a case-by-case basis. If wounds are not healing, please provide clinical information as to why ongoing reimbursement is required.
114

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.

Other review policies

For Inderal-LA: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026